Industry

IMVARIA Reports Multi-Site Clinical Experience With FDA-Authorized AI Diagnostic Service for Idiopathic Pulmonary Fibrosis at ATS 2025

Presenting real-world use of Fibresolve, the first-of-its-kind AI-powered adjunctive diagnostic service supporting assessment of suspected Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF) BERKELEY, Calif.–(BUSINESS WIRE)–#ATS—IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today reported results from multi-site clinical experiences with IMVARIA’s diagnostic referral service, where pulmonologists send cases for AI-supported … [Read more…]

Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia

Preclinical research demonstrates that a single administration of BE-102 provides continuous secretion of active alkaline phosphatase (ALP) in vivo out to 6 months No safety findings observed in long-term pharmacology studies Data presented at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting CAMBRIDGE, Mass.–(BUSINESS WIRE)–Be Biopharma, Inc. (“Be Bio”), a clinical-stage … [Read more…]

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

– Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin – – Additional 42-Month Data Reinforce Vutrisiran’s Impact on the Risk of All-Cause Mortality and Further Underscore the Effect on Cardiovascular Mortality – – Vutrisiran Demonstrated Substantial Benefit Across a Range of Cardiovascular … [Read more…]

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearance for Patients Being Assessed for Alzheimer’s Disease. — —Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — MALVERN, Pa., & TOKYO–(BUSINESS WIRE)–#IVD–Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted … [Read more…]

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company’s previously announced … [Read more…]

IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes

NEW YORK–(BUSINESS WIRE)–IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% … [Read more…]

Liberate Bio Announces Presentation to Update on RAPTOR LNP Platform and CAR-M Therapeutic Programs

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Liberate Bio, Inc., a biotechnology company developing medicines which efficiently and selectively deliver payloads to immune cells while bypassing the live, announced an oral presentation by Melissa Deck – Director of Platform, demonstrating the success of Liberate’s RAPTOR™ screening platform and NHP data for the company’s first lead candidates at the Oligonucleotide and … [Read more…]

JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising CNS Uptake at American Society of Gene and Cell Therapy 28th Annual Meeting

– Research Highlights the Potential of JCR’s Proprietary J-Brain Cargo® Technology to Facilitate Efficient Delivery of an AAV Gene Therapy to the Central Nervous System – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy research programs at the … [Read more…]

The One Show Announces Historic Win: Klick Health Becomes First Health Agency to Ever Receive An Agency of the Year Accolade

World’s largest independent health agency trailblazes through Creative Week with 27 The One Show Pencils, 27 ADC Annual Awards Cubes, 26 Clios, and more NEW YORK & TORONTO–(BUSINESS WIRE)–#Advertising—Klick Health is capping off The One Club’s Creative Week tonight with a groundbreaking win, becoming the first health agency in The One Show’s 52-year history to … [Read more…]

STAAR Surgical Announces $30 Million Share Repurchase Authorization

LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. … [Read more…]